Union Bancaire Privee UBP SA sold 44,839 shares of Teva Pharmaceutical Industries in the first quarter, decreasing its overall stake by 5.7%. The firm still retains 741,433 shares, underscoring its ongoing position in the global pharmaceutical company.
Union Bancaire Privee UBP SA Sells 44,839 Shares of Teva Pharmaceutical Industries Ltd. $TEVA
Key Takeaways:
- Union Bancaire Privee UBP SA sold 44,839 Teva shares in Q1.
- This transaction resulted in a 5.7% reduction in the firm’s stake.
- The fund still holds 741,433 shares after the sale.
- The disclosure was part of an SEC filing.
- Teva Pharmaceutical Industries trades on NYSE under the symbol TEVA.
A Significant Reduction in Stake
Union Bancaire Privee UBP SA recently decreased its stake in Teva Pharmaceutical Industries Ltd. by 5.7% during the first quarter of the year. According to the firm’s most recent filing with the Securities and Exchange Commission, this move involved selling a total of 44,839 shares. Despite this sizable transaction, the investment group remains a significant shareholder with 741,433 shares still under its management.
SEC Filings and Financial Disclosure
The information regarding Union Bancaire Privee UBP SA’s share sale comes from official data compiled by the SEC. Such filings provide transparency into the portfolio decisions of large institutional investors. The specifics of the transaction, including the exact number of shares sold and the percentage change, are documented in the filing.
What It Means for Teva
Teva Pharmaceutical Industries operates as a major player on the New York Stock Exchange under the ticker symbol TEVA. Institutional activity such as this highlights ongoing shifts in investor positioning within the pharmaceutical sector. Although the sale reflects Union Bancaire Privee UBP SA’s decision to reduce some of its exposure, the firm’s continued holdings in Teva underscore its lasting interest in the company’s market performance.